Genpact (G)
(Real Time Quote from BATS)
$38.52 USD
-0.48 (-1.23%)
Updated Sep 17, 2024 03:54 PM ET
After-Market: $38.56 +0.04 (0.10%) 4:14 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.52 USD
-0.48 (-1.23%)
Updated Sep 17, 2024 03:54 PM ET
After-Market: $38.56 +0.04 (0.10%) 4:14 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Zacks News
Xerox (XRX) to Benefit From Its Go Inspire Buyout: Here's How
by Zacks Equity Research
The acquisition should help Xerox (XRX) expand its Digital Services business and bring more innovation to its solutions.
Here's Why Investors Should Buy ICF International (ICFI) Now
by Zacks Equity Research
Strategic acquisitions and a strong balance sheet are aiding ICF International (ICFI) stock.
Reasons to Retain Maximus (MMS) Stock in Your Portfolio For Now
by Zacks Equity Research
With more than 40 years of experience, Maximus (MMS) has grown to be a leading operator of government health and human services programs globally.
6 Reasons to Add Paychex (PAYX) Stock to Your Portfolio Now
by Zacks Equity Research
Paychex's (PAYX) efforts to capitalize on the rising opportunities in the professional employer organization industry look impressive. Acquisitions help boost revenue growth.
G vs. PAYX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
G vs. PAYX: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Automatic Data Processing, Paychex and Genpact
by Zacks Equity Research
Automatic Data Processing, Paychex and Genpact have been highlighted in this Industry Outlook article.
3 Stocks to Watch From the Promising Outsourcing Space
by Sanjana Goswami
The Zacks Outsourcing industry seeks to benefit from the coronavirus-driven dependency on technology and accelerated adoption of cloud infrastructure. ADP, PAYX and G are well-positioned to witness the surge in demand.
6 Reasons Why Investors Should Buy Genpact (G) Stock Now
by Zacks Equity Research
Acquisitions have helped Genpact (G) expand its portfolio and gain new domain expertise. Artificial Intelligence offers the company solid growth opportunities.
4 Reasons to Buy Cross Country Healthcare (CCRN) Stock Now
by Zacks Equity Research
Cross Country Healthcare (CCRN) is currently benefiting from its investments in headcount and technology.
G or PAYX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
G vs. PAYX: Which Stock Is the Better Value Option?
Why Genpact (G) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
G vs. PAYX: Which Stock Is the Better Value Option?
by Zacks Equity Research
G vs. PAYX: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Automatic Data Processing, Paychex, and Genpact
by Zacks Equity Research
Automatic Data Processing, Paychex, and Genpact are part of Zacks Industry Outlook article.
3 Outsourcing Stocks to Strengthen Your Portfolio Now
by Sanjana Goswami
As the industry seeks to benefit from the COVID-driven reliance on technology and the accelerated uptake of cloud infrastructure, investing in outsourcing stocks like ADP, PAYX, G can be a prudent move.
Wall Street Analysts Believe Genpact (G) Could Rally 31%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 30.9% in Genpact (G). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
G vs. PAYX: Which Stock Is the Better Value Option?
by Zacks Equity Research
G vs. PAYX: Which Stock Is the Better Value Option?
Genpact (G) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Genpact (G) delivered earnings and revenue surprises of 13.21% and 3.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ExlService Holdings (EXLS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ExlService Holdings (EXLS) delivered earnings and revenue surprises of 8.40% and 7.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Lockheed Martin, Boeing, Northrop Grumman, General Dynamics and Huntington Ingalls Industries
by Zacks Equity Research
Lockheed Martin, Boeing, Northrop Grumman, General Dynamics and Huntington Ingalls Industries are part of today's Analyst Blog.
Workday (WDAY) to Help Expand Genpact's Global Business
by Zacks Equity Research
The Workday (WDAY) platform will help drive process standardization across Genpact's teams to ensure secure data access for better decision-making.
Genpact's (G) Q4 Earnings Surpass Estimates, Improve Y/Y
by Zacks Equity Research
Genpact's (G) fourth-quarter 2021 revenues increase year over year.
G or PAYX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
G vs. PAYX: Which Stock Is the Better Value Option?
Genpact (G) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Genpact (G) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Industry Outlook Highlights Automatic Data Processing, Paychex and Genpact
by Zacks Equity Research
Automatic Data Processing, Paychex and Genpact are included in this Industry Outlook blog.
Genpact (G) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Genpact (G) delivered earnings and revenue surprises of 1.89% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?